Xin Gang, Du Juan, Zhu Lin, Yu Yun-hai, Li Yue, Liu Pei-shu
Department of Obstetrics & Gynecology, Qilu Hospital, Shandong University, Jinan 250012, China.
Zhonghua Yi Xue Za Zhi. 2011 Dec 20;91(47):3367-70.
To find the time window of normalization of tumor vasculature by endostar in tumor-bearing mice with ovarian cancer.
The nude murine model of ovarian cancer was established. The vasculature markers α-SMA (alpha-smooth muscle actin) and collagen IV covered tumor vessels and hypoxic zone following the treatment of endostar were monitored. According to the changes of microvascular morphology and tumor hypoxia zone, the time window was identified. Furthermore the treatment protocols of scheduling dosing of cisplatin plus endostar at different time points were designed. After treatment tumor volume, the parameters of microvascular density (MVD) and PCNA (proliferating cell nuclear antigen) were monitored to evaluate the effects of different protocols.
At Days 4 and 6 post-treatment, more α-SMA and collagen IV covered vessels could be observed. The amount of microvasculature expressed α-SMA on days 4 compared with control was (15.3 ± 5.2) vs (4.3 ± 2.1)/mm(2) (P < 0.01); at Day 6, the result was (16.4 ± 4.6) vs (6.6 ± 2.4)/mm(2)(P < 0.01). The expression of collagen IV had a similar change. And the numbers of microvasculature expressing collagen IV was (14.7 ± 4.3) vs (6.7 ± 5.1)/mm(2) at Days 4 and 6 (P < 0.01); (18.4 ± 5.5) vs (7.1 ± 1.7)/mm(2) (P < 0.01). The expression of HIF-1α decreased in hypoxic area. In the rhES + DDP (d4-6) group, the value of microvessel density (MVD) decreased and the expression of PCNA significantly decreased versus other groups.
Endostar may normalize the tumor vasculature. And the time window is found at Days 4-6 post-treatment. During the time of vascular normalization, a combination therapy of endostar plus cisplatin has optimal efficacies.
探寻恩度使荷卵巢癌小鼠肿瘤血管正常化的时间窗。
建立卵巢癌裸鼠模型。监测恩度治疗后肿瘤血管标志物α-平滑肌肌动蛋白(α-SMA)和IV型胶原覆盖的肿瘤血管及缺氧区域。根据微血管形态和肿瘤缺氧区域的变化确定时间窗。此外,设计了在不同时间点顺铂联合恩度的给药方案。治疗后监测肿瘤体积、微血管密度(MVD)和增殖细胞核抗原(PCNA)参数,以评估不同方案的效果。
治疗后第4天和第6天,可观察到更多α-SMA和IV型胶原覆盖的血管。与对照组相比,第4天表达α-SMA的微血管数量为(15.3±5.2)/mm² 对(4.3±2.1)/mm²(P<0.01);第6天,结果为(16.4±4.6)/mm² 对(6.6±2.4)/mm²(P<0.01)。IV型胶原的表达有类似变化。第4天和第6天表达IV型胶原的微血管数量分别为(14.7±4.3)/mm² 对(6.7±5.1)/mm²(P<0.01);(18.4±5.5)/mm² 对(7.1±1.7)/mm²(P<0.01)。缺氧区域缺氧诱导因子-1α(HIF-1α)表达降低。与其他组相比,重组人血管内皮抑制素+顺铂(d4-6)组微血管密度(MVD)值降低,PCNA表达显著降低。
恩度可能使肿瘤血管正常化。时间窗为治疗后第4至6天。在血管正常化期间,恩度联合顺铂的联合治疗具有最佳疗效。